SCHEMBL12378818

SCHEMBL12378818

CC(=O)CNC(=O)C1(c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
HTT P42858 1/20 0.56
LMNA P02545 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
PKM P14618 1/20 0.52
HDAC4 P56524 3/20 0.51
TSHR P16473 1/20 0.50
CHRM2 P08172 1/20 0.49
ERCC1 P07992 1/20 0.48
ERCC4 Q92889 1/20 0.48
GLS O94925 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HSD11B1 P28845 2/20 0.46
THRB P10828 1/20 0.46
HDAC1 Q13547 1/20 0.46
CHRM5 P08912 1/20 0.45
CHRM3 P20309 1/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2722768 0.83 SMN1; SMN2 (0.59) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL10205809 0.83 SMN1; SMN2 (0.52) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL9829124 0.79 SMN1; SMN2 (0.68) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL3867684 0.79 SMN1; SMN2 (0.55) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL8572144 0.77 HDAC4 (0.59) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL20060916 0.77 SMN1; SMN2 (0.65) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL14067363 0.75 SMN1; SMN2 (0.68) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL9831308 0.74 SMN1; SMN2 (0.61) SMN1; SMN2HTTLMNANPSR1L3MBTL1
SCHEMBL890180 0.74 AKR1C1 (0.57) LMNAPKMHDAC4ALDH1A1HSD11B1
SCHEMBL3866449 0.73 SMN1; SMN2 (0.60) SMN1; SMN2HTTLMNANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 SMN1; SMN2 2141/4885HTT 3140/4885LMNA 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.